Hyundai Bioscience Co., Ltd. released exciting efficacy results for its new 'NOAEL Cancer Therapy' at the 2019 Global Bio Conference, an event hosted by the Korea FDA. Polytaxel, the first anticancer drug tested as part of the efficacy study, demonstrated unprecedented efficiency in combatting pancreatic tumors, indicating strong potential for cancer eradication while also minimizing the often brutal side effects of cancer treatment. The NOAEL value, which refers to the "No Observed Adverse Effect Level" designation applied to drugs in non-clinical risk assessment, determines the highest dose of a given drug at which there will not be an observed toxic or adverse effect. Animal testing results for Polytaxel determine that, even within the designated NOAEL dose limit, the treatment destroyed tumors almost completely without generating toxicity-induced side effects, an impressive achievement poised to attract international attention. The side effects of the treatment are also less damaging than those of traditional chemotherapy. In toxicity-induced body weight change observation, animals treated with Docetaxel experienced on average a 19.1% decrease in body weight over the course of treatment, while animals treated with Polytaxel experienced on average a 5.2% increase in body weight. In cases where drug toxicity was not exhibited during blood circulation, body weight tended to stay the same or increased by a small margin.